Recently stock market analysts have updated their consensus ratings on shares of Jaguar Animal Health, Inc. (JAGX).
Most recent broker ratings
06/10/2016 – Jaguar Animal Health, Inc. had its “buy” rating reiterated by analysts at Aegis Capital. They now have a USD 10 price target on the stock.
08/27/2015 – Feltl & Co. began new coverage on Jaguar Animal Health, Inc. giving the company a “strong-buy” rating.
Jaguar Animal Health, Inc. has a 50 day moving average of 1.16 and a 200 day moving average of 1.52. The stock’s market capitalization is 9.90M, it has a 52-week low of 0.82 and a 52-week high of 4.70.
The share price of the company (JAGX) was up +0.79%, with a high of 1.00during the day and the volume of Jaguar Animal Health, Inc. shares traded was 100205.
Jaguar Animal Health, Inc. is an animal health company. It is focused on developing and commercializing gastrointestinal products for companion and production animals, foals, and horses. Canalevia is its prescription drug product candidate, intended for treatment of various forms of diarrhea in dogs. Canalevia is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient (API) isolated and purified from the Croton lechleri tree. It is developing a pipeline of prescription drug product candidates and non-prescription (non-drug) products to address needs in animal health. As of December 31, 2016, its pipeline includes prescription drug product candidates for nine indications across multiple species, and non-prescription products targeting seven species. Its product candidates include Canalevia, Species-specific formulations of crofelemer, Equilevia, Virend (topical), Species-specific formulations of NP-500, Neonorm Calf and Species-specific formulations of Neonorm.